Future studies should evaluate very low LDL-C in unique populations (e.g., heart failure, stroke), assess combination therapies (e.g., PCSK9 inhibitors + inclisiran), investigate non-cardiovascular effects (e.g., cancer, infection risk) with longer follow-ups, and incorporate patient-reported outcomes and quality-of-life measures. This evidence concerns the gene PCSK9 and infection.